Jörn Rau - Concepedia

Author

Jörn Rau

Philipps University of Marburg ORCID

Also Known As

J Rau, J. -P. Rau, J. Rau, J. Rau, Joern Rau, Jörn Rau, Rau, J.

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Philipps University of Marburg Kliniken Essen-Mitte Charité - Universitätsmedizin Berlin Inserm Institut du Cerveau

About

Jörn Rau is an author at Philipps University of Marburg specializing in medicine, cancer therapeutics, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	640
2	Health Sciences	3	3	185
3	Social Sciences	2	2	165
4	Education	1	1	57
5	Applied Physiology	1	1	77

Jörn Rau

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Neurostimulation for Parkinson's Disease with Early Motor Complications W.M. Michael Schuepbach, Jörn Rau, Karina Knudsen, New England Journal of Medicine	2013	1.4K
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial Eugénie Lhommée, Lars Wojtecki, Virginie Czernecki, The Lancet Neurology Subthalamic StimulationStimulation DeviceEarly Motor ComplicationsParkinson DiseaseRehabilitation	2018	163
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: Concept and standards of the EARLYSTIM-study Günther Deuschl, Michaël Schüpbach, Karina Knudsen, Parkinsonism & Related Disorders Earlier Disease StageNeurophysiologyNeuroanatomyParkinson DiseaseMedicine	2012	126
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy Klaus Baumann, Andreas du Bois, Werner Meier, Annals of Oncology Ago 2.11MedicinePharmacologyClinical TrialsGynecology	2012	84
The effect of maximal exercise on the activity of neutrophil granulocytes in highly trained athletes in a moderate training period Volker Hack, G. Ströbel, Jörn Rau, European Journal of Applied Physiology InflammationSport PhysiologyPhysical ActivityKinesiologyGranulocyte	1992	77
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer Ignace Vergote, Andreas du Bois, Anne Floquet, Gynecologic Oncology	2019	67
Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications Michael T. Barbe, Lisa Tonder, Paul Krack, Movement Disorders	2019	67
Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16). Andreas du Bois, Anne Floquet, Jae‐Weon Kim, Journal of Clinical Oncology Cancer ManagementGynecologyPathologyPharmacotherapyGynecology Oncology	2013	65
Cognitive Behaviour Therapy Complemented with Emotion Regulation Training for Patients with Persistent Physical Symptoms: A Randomised Clinical Trial Maria Kleinstäuber, Christine Allwang, Josef Bailer, Psychotherapy and Psychosomatics	2019	60
The psychoeducational program for children with epilepsy and their parents (FAMOSES): Results of a controlled pilot study and a survey of parent satisfaction over a five-year period Margarete Pfäfflin, F. Petermann, Jörn Rau, Epilepsy & Behavior Child PsychologyChild Well-beingFamily InvolvementParent SatisfactionPediatrics	2012	57

Page 1